AlphaCore Capital’s Heron Therapeutics HRTX Stock Holding History

AlphaCore Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-500	Closed	-$6K	–	180
2020 Q1	$6K	Buy	+500	New	+$9.4K	﹤0.01%	243

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaCore Capital's HRTX Position: Q2 2020 in Review

AlphaCore Capital sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 500 shares — an estimated $6K sold.

AlphaCore Capital first reported a position in HRTX in Q1 2020 and held it in 1 quarter. The position peaked at $6K in Q1 2020. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

AlphaCore Capital reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
AlphaCore Capital sold 500 Heron Therapeutics shares in Q2 2020, an estimated $6K.
AlphaCore Capital first reported a position in Heron Therapeutics in Q1 2020 and held it in 1 quarter.
AlphaCore Capital's Heron Therapeutics position peaked at $6K in Q1 2020.
190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on AlphaCore Capital's 13F filing for Q2 2020, filed 14 Aug 2020.